drugset / Trial / NCT01068249

Letrozole and RAD001 With Advanced or Recurrent Endometrial Cancer

NCT01068249 ↗

Phase 2 Active not recruiting 42 enrolled M.D. Anderson Cancer Center Novartis · collab
NaSingle-groupOpen-labelTreatment

Summary

The goal of this clinical research study is to learn if the combination of RAD001 (everolimus) and Femara (letrozole) can help to control recurrent or progressive endometrial cancer. The safety of this drug combination will also be studied.

Timeline

Start
2010-04-30
Primary completion
2022-04
Completion
2028-04-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Everolimus Small molecule 10 mg Oral
Subject Letrozole Other / unclassified 2.5 mg Oral

Indications